Nephrectomy after complete response to immune checkpoint inhibitors for metastatic renal cell carcinoma (mRCC): A new surgical challenge?

Abstract only 707 Background: In the current era of Immune checkpoint inhibitors (ICI), the role and timing of nephrectomy in the case of complete response on metastatic sites is still unknown. We aimed to evaluate the feasibility of nephrectomy for residual disease in patients with metastatic renal...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical oncology Vol. 38; no. 6_suppl; p. 707
Main Authors: Pignot, Geraldine, Thiery-Vuillemin, Antoine, Walz, Jochen, Lang, Herve, Werle, Pierre, Balssa, Loic, Geoffrois, Lionnel, Leblanc, Louis, Albiges, Laurence, Di Nunno, Vincenzo, Bensalah, Karim, Ladoire, Sylvain, Gravis, Gwenaelle, Barthelemy, Philippe
Format: Journal Article
Language:English
Published: 20-02-2020
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Abstract only 707 Background: In the current era of Immune checkpoint inhibitors (ICI), the role and timing of nephrectomy in the case of complete response on metastatic sites is still unknown. We aimed to evaluate the feasibility of nephrectomy for residual disease in patients with metastatic renal cell carcinoma (mRCC) and complete response (CR) on metastatic sites following ICI. Methods: Patients who underwent partial or radical nephrectomy after prior ICI between 2015 and 2018 were retrospectively included and clinicopathological data were reviewed. Perioperative data and postoperative outcomes were recorded. Results: Eleven patients without initial cytoreductive nephrectomy at diagnosis underwent delayed nephrectomy after long ICI administration because of complete response on metastatic sites. Median age was 59.8 years [38-67]. All patients had clear cell RCC on the initial biopsy. IMDC prognostic group was intermediate (81.8%) or poor (18.2%). ICI was administered as first-line therapy in 36.4% of cases (4/11) and as second-line option after TKI in 63.6% of cases (7/11). Treatments regimens were: nivolumab + ipilimumab (n = 3), nivolumab + tivozanib (n = 2) or nivolumab alone (n = 6). The median duration of ICI treatment was 10 months (range: 3-38 months) and the mean number of cycles was 27 (range: 6-75). Median operative time was 243 minutes [135-345] and mean blood loss was 909 cc [40-4000]. In 81.8% (n = 9) of the cases, surgeons experienced challenges for finding dissection planes due to inflammatory infiltration. The 30-day Clavien-Dindo postoperative complication rate was 54.6%, including 1 surgery-related death. Pathological report showed lymphocyte and/or macrophage infiltration in 54.6% and complete pathological response in 2 cases. Median follow-up was 15 months, with 73% of patients free from progression and 54% free from systemic treatment at 1 year. Conclusions: Nephrectomy following ICI for mRCC could allow achieving CR in selected patients. Due to technically complexity and complications rates, this surgery should be performed in centers with extensive experience.
AbstractList Abstract only 707 Background: In the current era of Immune checkpoint inhibitors (ICI), the role and timing of nephrectomy in the case of complete response on metastatic sites is still unknown. We aimed to evaluate the feasibility of nephrectomy for residual disease in patients with metastatic renal cell carcinoma (mRCC) and complete response (CR) on metastatic sites following ICI. Methods: Patients who underwent partial or radical nephrectomy after prior ICI between 2015 and 2018 were retrospectively included and clinicopathological data were reviewed. Perioperative data and postoperative outcomes were recorded. Results: Eleven patients without initial cytoreductive nephrectomy at diagnosis underwent delayed nephrectomy after long ICI administration because of complete response on metastatic sites. Median age was 59.8 years [38-67]. All patients had clear cell RCC on the initial biopsy. IMDC prognostic group was intermediate (81.8%) or poor (18.2%). ICI was administered as first-line therapy in 36.4% of cases (4/11) and as second-line option after TKI in 63.6% of cases (7/11). Treatments regimens were: nivolumab + ipilimumab (n = 3), nivolumab + tivozanib (n = 2) or nivolumab alone (n = 6). The median duration of ICI treatment was 10 months (range: 3-38 months) and the mean number of cycles was 27 (range: 6-75). Median operative time was 243 minutes [135-345] and mean blood loss was 909 cc [40-4000]. In 81.8% (n = 9) of the cases, surgeons experienced challenges for finding dissection planes due to inflammatory infiltration. The 30-day Clavien-Dindo postoperative complication rate was 54.6%, including 1 surgery-related death. Pathological report showed lymphocyte and/or macrophage infiltration in 54.6% and complete pathological response in 2 cases. Median follow-up was 15 months, with 73% of patients free from progression and 54% free from systemic treatment at 1 year. Conclusions: Nephrectomy following ICI for mRCC could allow achieving CR in selected patients. Due to technically complexity and complications rates, this surgery should be performed in centers with extensive experience.
Author Geoffrois, Lionnel
Bensalah, Karim
Barthelemy, Philippe
Di Nunno, Vincenzo
Gravis, Gwenaelle
Ladoire, Sylvain
Balssa, Loic
Pignot, Geraldine
Werle, Pierre
Lang, Herve
Walz, Jochen
Leblanc, Louis
Thiery-Vuillemin, Antoine
Albiges, Laurence
Author_xml – sequence: 1
  givenname: Geraldine
  surname: Pignot
  fullname: Pignot, Geraldine
  organization: Department of Surgical Oncology, Institut Paoli-Calmettes, Marseille, France
– sequence: 2
  givenname: Antoine
  surname: Thiery-Vuillemin
  fullname: Thiery-Vuillemin, Antoine
  organization: University Hospital Jean Minjoz, Besançon, France
– sequence: 3
  givenname: Jochen
  surname: Walz
  fullname: Walz, Jochen
  organization: Institut Paoli-Calmettes, Chirurgie Oncologique 2, Marseille, France
– sequence: 4
  givenname: Herve
  surname: Lang
  fullname: Lang, Herve
  organization: Department of Urology, CHU Strasbourg, Strasbourg University, Strasbourg, France
– sequence: 5
  givenname: Pierre
  surname: Werle
  fullname: Werle, Pierre
  organization: Urology Department, University Hospital of Strasbourg, Strasbourg, France
– sequence: 6
  givenname: Loic
  surname: Balssa
  fullname: Balssa, Loic
  organization: Urology Department, Chru Besancon, Besancon, France
– sequence: 7
  givenname: Lionnel
  surname: Geoffrois
  fullname: Geoffrois, Lionnel
  organization: Centre Alexis Vautrin, Vandoeuvre-Lès-Nancy, France
– sequence: 8
  givenname: Louis
  surname: Leblanc
  fullname: Leblanc, Louis
  organization: Department of Urology, CHRU Nancy, Nancy, France
– sequence: 9
  givenname: Laurence
  surname: Albiges
  fullname: Albiges, Laurence
  organization: Medical Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France
– sequence: 10
  givenname: Vincenzo
  surname: Di Nunno
  fullname: Di Nunno, Vincenzo
  organization: Department of medical oncology, Institut Gustave Roussy, Villejuif, France
– sequence: 11
  givenname: Karim
  surname: Bensalah
  fullname: Bensalah, Karim
  organization: University Hospital Pontchaillou Service d’urologie CHU Rennes, Université de Rennes, Rennes, France
– sequence: 12
  givenname: Sylvain
  surname: Ladoire
  fullname: Ladoire, Sylvain
  organization: Department of Medical Oncology, Center GF Leclerc, Dijon, France
– sequence: 13
  givenname: Gwenaelle
  surname: Gravis
  fullname: Gravis, Gwenaelle
  organization: Institut Paoli-Calmettes, Marseille, France
– sequence: 14
  givenname: Philippe
  surname: Barthelemy
  fullname: Barthelemy, Philippe
  organization: Hôpitaux Universitaires de Strasbourg, Strasbourg, France
BookMark eNot0M9KxDAQBvAgCq6rz2COetiaNE2TehEp_kUURMFbSLOT3WiblCSL7CP41nbRy3yXmYHvd4T2ffCA0CklBS0JuXhsX4qSlKRgsqhV2oxjXwgi9tCM8lIshOB8H82IYOWCSvZxiI5S-iSEVpLxGfp5hnEdweQwbLG2GSI2YRh7yIAjpDH4BDgH7IZh4wGbNZivMTifsfNr17kcYsI2RDxA1inr7Mx053WPDfTT0NE4HwaNz4bXtj2_xNfYwzdOm7hyZre11n0PfgVXx-jA6j7ByX_O0fvtzVt7v3h6uXtor58WhpKpj7bVkoA0NbWV7JjhnahlbaRljVh2XAOvlg0tte4aWnEQnbR103TSdLrmNbNsjsTfXxNDShGsGqMbdNwqStROVE2iaieqmFT_omoSZb91KXGf
CitedBy_id crossref_primary_10_1200_OP_21_00446
ContentType Journal Article
DBID AAYXX
CITATION
DOI 10.1200/JCO.2020.38.6_suppl.707
DatabaseName CrossRef
DatabaseTitle CrossRef
DatabaseTitleList CrossRef
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Pharmacy, Therapeutics, & Pharmacology
EISSN 1527-7755
EndPage 707
ExternalDocumentID 10_1200_JCO_2020_38_6_suppl_707
GroupedDBID ---
.55
0R~
18M
2WC
34G
39C
4.4
53G
5GY
5RE
8F7
AAQQT
AARDX
AAWTL
AAYEP
AAYXX
ABJNI
ABOCM
ACGFO
ACGFS
ACGUR
ADBBV
AEGXH
AENEX
AIAGR
ALMA_UNASSIGNED_HOLDINGS
AWKKM
BAWUL
C45
CITATION
CS3
DIK
EBS
EJD
F5P
F9R
FBNNL
FD8
GX1
H13
HZ~
IH2
K-O
KQ8
L7B
LSO
MJL
N9A
O9-
OK1
OVD
OWW
P2P
QTD
R1G
RHI
RLZ
RUC
SJN
SV3
TEORI
TR2
TWZ
UDS
VVN
WH7
X7M
YCJ
YFH
YQY
ID FETCH-LOGICAL-c1027-af4d0e8c61f48b3c5b7686c8f397db5ae54d912aab9145e7b8f699b8cba6563f3
ISSN 0732-183X
IngestDate Thu Nov 21 21:15:10 EST 2024
IsPeerReviewed true
IsScholarly true
Issue 6_suppl
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c1027-af4d0e8c61f48b3c5b7686c8f397db5ae54d912aab9145e7b8f699b8cba6563f3
PageCount 1
ParticipantIDs crossref_primary_10_1200_JCO_2020_38_6_suppl_707
PublicationCentury 2000
PublicationDate 2020-02-20
PublicationDateYYYYMMDD 2020-02-20
PublicationDate_xml – month: 02
  year: 2020
  text: 2020-02-20
  day: 20
PublicationDecade 2020
PublicationTitle Journal of clinical oncology
PublicationYear 2020
SSID ssj0014835
Score 2.368287
Snippet Abstract only 707 Background: In the current era of Immune checkpoint inhibitors (ICI), the role and timing of nephrectomy in the case of complete response on...
SourceID crossref
SourceType Aggregation Database
StartPage 707
Title Nephrectomy after complete response to immune checkpoint inhibitors for metastatic renal cell carcinoma (mRCC): A new surgical challenge?
Volume 38
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lj9MwELbKIiEuCBYQb_kAK1A33TR2EocLWpWiRYjdCgrsLbIdByJosurjUP4B_5qZOA-zCMEeuEStVVtJ5ut4ZjwzHyGP4yzUcZwlnuSJ8riMlJcwX3hKBsKXJhI2efzofXx8Kl5O-XQwaHlH-7H_KmkYA1lj5ewFpN0tCgPwGWQOV5A6XP9J7scGxaPX1WLbEIDXWeNgGw-XNh-2JssosC7EDEFk-utZVZTIFPClUEVNvoOphwuzllhtVLd4RpMVQ_zYyFoXZbWQaJku3k0mT4LEFreDeT5cbZZWkeqWouVc3qBj_nYlmVWpfwntz4rPZbW28XqMlzkH_3Mk7t56HzdYwLjouh9Uzk8-yW_f7akAPFqfbtRExY8wv9MNdIBXi4XjvqMPYxZ4oIFO7dbV6OsgBgfBdvptFToTDnCjdIX0qI6Oji3NbrPdN99-20kCS5I9ORnhvYyYGDUrjbr5bu_uc3tql-mIPlaAB4aTkxQXSplIm4XSGLsgXA5AQ9axgNdvuuMvLiwzbPvETWIiLHTwhztyzCrHPppfJ9caydJDi8gbZGDKXXLlbZO6sUv2ZrZJ-nafzvuav9U-3aOzvn369ib54SCY1gimLYJpi2C6rqhFMO0RTHsEU0Aw7RFMawRTRDDtEEyfIn6fPaeHFLBLW-zSDrsvbpEPr6bzyZHXEIZ4Guzk2JM5z3wjdDTOuVBMhwqc6UiLHIzuTIXShDxLxoGUKhnz0MRK5FGSKKGVBLeG5ew22Smr0twhlCVGZblMJIsyHoUwJ8hykzGhVO5zru4Sv33f6ZntC5P-Rdb3Lj7lPrna_xMekJ31cmMekkurbPOoBsxPpgG5ew
link.rule.ids 315,782,786,27933,27934
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Nephrectomy+after+complete+response+to+immune+checkpoint+inhibitors+for+metastatic+renal+cell+carcinoma+%28mRCC%29%3A+A+new+surgical+challenge%3F&rft.jtitle=Journal+of+clinical+oncology&rft.au=Pignot%2C+Geraldine&rft.au=Thiery-Vuillemin%2C+Antoine&rft.au=Walz%2C+Jochen&rft.au=Lang%2C+Herve&rft.date=2020-02-20&rft.issn=0732-183X&rft.eissn=1527-7755&rft.volume=38&rft.issue=6_suppl&rft.spage=707&rft.epage=707&rft_id=info:doi/10.1200%2FJCO.2020.38.6_suppl.707&rft.externalDBID=n%2Fa&rft.externalDocID=10_1200_JCO_2020_38_6_suppl_707
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0732-183X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0732-183X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0732-183X&client=summon